EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet-Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana iD und 1 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70660 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Clara Laffitte Redondo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Génomique et Pharmacogénomique, CHU Kremlin Bicêtre, APHP, Paris, France. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Chemical and Drug Induced Liver Injury, Cytochrome P-450 CYP3A. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly understood. This case series explores the role of genetic polymorphisms affecting the enzymes and transporters involved in their pharmacokinetics, as well as detoxification mechanisms (CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1). Six cases of hepatotoxicity under CFTR modulators were assessed using the RECAM score. Among the genetic polymorphisms assessed, CYP3A4*22 (rs35599367) allele had higher allele frequency than in the European population, which usually does not express CYP3A5. This genetic variant, reducing CYP3A activity, could decrease the elimination of CFTR modulators and increase the risk of liver toxicity. Other genetic factors may also be involved. Further studies are needed to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorChemical and Drug Induced Liver InjuryCytochrome P-450 CYP3AQuinolonesAminophenolsHumansMaleFemaleAdultYoung AdultPolymorphism, GeneticAdolescentGene FrequencyChild

Stichwörter der Autor:innen

CFTR modulatorsCYP3A4hepatotoxicityivacaftorpharmacogenetics

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCytochrome P-450 CYP3ACYP3A4 protein, humanCFTR protein, humanQuinolonesAminophenols

Autor:innen und Institutionen

  • Service de Médecine Génomique et Pharmacogénomique, CHU Kremlin Bicêtre, APHP, Paris, France.
  • Centre Régional de Pharmacovigilance, Service de Pharmacologie, Hôpital Cochin, AP-HP, Université de Paris; Réseau Français de Pharmacovigilance, Paris, France.
  • Service de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Université de Paris-Cité, Paris, France.
  • Centre Régional de Pharmacovigilance, Service de Pharmacologie Clinique, Institut de Biologie, CHU Hôtel Dieu, Nantes, France.
  • Centre de Ressources et de Compétence pour la Mucoviscidose, Hôpital Mère-Enfant, Nantes, France.
  • INSERM U1151, Université Paris Cité, Hôpital Necker Enfants Malades, APHP, Paris, France.

ORCID-Profile: Laurent Chouchana, Estelle Ayme-Dietrich

Zitieren

APA

Laffitte Redondo, C., Bourdin, V., Ait Tayeb, A. E. K., Benaboud, S., Martins, I., Joyau, C., Benhamida, M., Sermet-Gaudelus, I., Martin, C., Burgel, P. R., Verstuyft, C., Chouchana, L., & Ayme-Dietrich, E. (2026). A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70660

Vancouver

Laffitte Redondo C, Bourdin V, Ait Tayeb AEK, Benaboud S, Martins I, Joyau C, et al. A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70660

BibTeX
@article{LaffitteRedondo2026,
  author = {Laffitte Redondo, Clara and Bourdin, Venceslas and Ait Tayeb, Abd El Kader and Benaboud, Sihem and Martins, Inès and Joyau, Caroline and Benhamida, Myriam and Sermet-Gaudelus, Isabelle and Martin, Clémence and Burgel, Pierre Régis and Verstuyft, Céline and Chouchana, Laurent and Ayme-Dietrich, Estelle},
  title = {A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70660}
}
Kostenlos starten →